Combined Use of a SERCA Inhibitor and a Calmodulin Antagonist
The administration of a Calmodulin antagonist such as Trifluoperazine in combination with a SERCA inhibitor like
Thapsigargin is surprisingly useful in the treatment of tumors, which are in particular characterized by the overexpression of the SEC62 gene/Sec62 protein. They showed that the combined use of a SERCA inhibitor and a Calmodulin antagonist acts 1) on the inhibition of cell migration and 2) counteracts the reduced efficiency of SERCA inhibitor observed in the treatment of tumors overexpressing SEC62 gene /protein, thereby providing an effective treatment of these tumors. Notably, the Calmodulin antagonist Trifluoperazine is an approved antipsychotic und antiemetic drug.
Weitere Informationen: PDF
Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Tel.: +49 (0)681/302-71302
Ansprechpartner
Dipl.-Kfm. Axel Koch (MBA), Dr. Conny Clausen, Dr. Nicole Comtesse, Dr. Frank Döbrich
